New agents and future directions in biotherapy

Area of Science:

• Oncology
• Biotherapy
• Cancer Therapeutics

Background:

• Biotherapy agents are increasingly studied for cancer treatment, both alone and with conventional therapies like chemotherapy.
• Key biotherapy classes include monoclonal antibodies (e.g., rituximab, trastuzumab), radioimmunotherapy, tyrosine kinase inhibitors, cancer vaccines, and angiogenesis inhibitors.

Purpose of the Study:

• To review the landscape of emerging biotherapy agents for cancer treatment.
• To highlight the diverse mechanisms of action and therapeutic potential of these novel agents.

Main Methods:

• Literature review of current research and clinical investigations into various biotherapy agents.
• Analysis of approved and investigational agents, including monoclonal antibodies, radioimmunotherapy, tyrosine kinase inhibitors, vaccines, and angiogenesis inhibitors.

Main Results:

• Monoclonal antibodies like rituximab and trastuzumab are under investigation.
• Radioimmunotherapy shows promise, particularly for lymphoma treatment.
• Tyrosine kinase inhibitor STI 571 is FDA-approved; cancer vaccines and angiogenesis inhibitors (e.g., endostatin, anti-VEGF, thalidomide) are under investigation.

Conclusions:

• A wide array of biotherapy agents are being developed to enhance cancer treatment strategies.
• These novel agents offer diverse mechanisms, targeting tumor cells directly or inhibiting tumor growth and vascularization.
• Ongoing research aims to integrate these biotherapies into effective single-agent or combination regimens.